The opioid crisis rages on, leaving a trail of broken lives and lost hope. In this desolate landscape, medication-assisted treatment (MAT) emerged as a beacon, offering a path to recovery. Among its champions: buprenorphine implants, tiny warriors nestled under the skin, promising to tame cravings and rebuild shattered dreams. But like any weapon, they can inflict as much harm as good. The recent FDA boxed warning on buprenorphine implants throws this reality into stark relief, sparking critical questions about balancing hope and accountability.
Why does the US FDA require proper boxed warnings for Cancer Therapies?
A Tale of Two Sides:
Buprenorphine, a partial opioid agonist, blocks the euphoric high of other opioids while easing withdrawal symptoms. This makes it a powerful ally in ...
